Zepbound dosing: weekly tirzepatide titration

Zepbound weekly titration chart

Zepbound is injected once weekly, any time of day, with or without food, in the abdomen, thigh, or upper arm. Rotate sites. Never share a pen or vial. This chart summarizes the U.S. label. It is not a prescription. Beema Health does not dispense Zepbound. A licensed clinician must prescribe and adjust doses. Weight loss is not guaranteed.

• Weeks 1-4: 2.5 mg once weekly (initiation only)
• Then 5 mg once weekly
• Optional further steps after at least 4 weeks each: 7.5 mg, 10 mg, 12.5 mg, 15 mg
• Maximum: 15 mg once weekly
• Weight-reduction maintenance: 5, 10, or 15 mg weekly
• OSA maintenance: 10 or 15 mg weekly

Why the 2.5 mg steps exist

SURMOUNT trials escalated by 2.5 mg about every four weeks to a maximum tolerated 10 or 15 mg in many protocols. Gastrointestinal adverse reactions (nausea, diarrhea, vomiting, constipation) clustered during escalation. Starting at 15 mg would not match how the medicine was studied or labeled.

If a step is rough, the prescriber can hold longer than four weeks before the next 2.5 mg increment. That is still labeled-style caution. Creating an unofficial dose by 'counting clicks' is not.

Weight-management versus OSA maintenance

For chronic weight management, 5 mg weekly is a labeled maintenance option, not only 15 mg. Some people do well and stay at 5 or 10 mg. SURMOUNT-1 still showed dose-related mean weight change, with the 15 mg arm producing the largest average reduction versus placebo. Averages are not individual guarantees.

For moderate to severe OSA in adults with obesity, recommended maintenance is 10 or 15 mg, matching SURMOUNT-OSA's maximum tolerated dose design. A person treated only for OSA should not assume 5 mg is the target without the prescriber saying so.

Devices, storage, and missed doses

Presentations include single-dose pens, single-dose vials, and in some strengths multi-dose vials or a KwikPen. Each has its own priming and storage rules. Travel and refrigeration are covered in the travel-with-Zepbound article.

If several consecutive weekly doses are missed, clinicians often restart or re-titrate rather than jumping back to 15 mg. Ask before using leftover high-dose pens after a long gap.

Safety checks that override the calendar

Zepbound has a boxed warning for rodent thyroid C-cell tumors and is contraindicated in MTC, MEN 2, and after serious hypersensitivity to tirzepatide. It is not recommended in severe gastroparesis. Severe GI loss can cause kidney injury. Stop and seek care for suspected pancreatitis. Insulin or sulfonylurea doses may need reduction. Tell surgical teams about the medicine because of aspiration risk.

Pregnancy planning requires a clinician conversation. None of these issues is fixed by staying on 2.5 mg without advice.

What happens after you reach a maintenance dose

SURMOUNT-4 showed that continuing tirzepatide after a lead-in period maintained much more of the weight reduction than switching to placebo. Reaching 10 or 15 mg is not a finish line after which the medicine is optional if the treatment goal remains weight maintenance. See GLP-1 maintenance dose and stopping tirzepatide.

Switching from Zepbound to Wegovy is a new prescription with no official milligram conversion table. See that switching article. Beema Health does not offer Zepbound. The medical weight-loss overview explains Beema telehealth visits without claiming a branded substitution.

Frequently asked questions

Sources

1. [1] Zepbound (tirzepatide) U.S. Prescribing Information, Eli Lilly
2. [2] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
3. [3] Lilly Medical: Zepbound dosing in moderate to severe OSA with obesity
4. [4] Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.